Some controversy exists about whether chemokine CCL17 exerts antitumor effects or suppresses immune responses in the NSCLC microenvironment (Nakanishi et al., 2006; de Chaisemartin et al., 2011). The gene discussed is CCL17; the disease is non-small cell lung carcinoma.